VASOACTIVE INTESTINAL POLYPEPTIDE VIP Test
Test Name: VASOACTIVE INTESTINAL POLYPEPTIDE VIP Test
Components: Plasma sample from Lavender Top (EDTA) tube
Price: 2690.0 AED
Sample Condition: 3 mL (1.5 mL min.) plasma from 1 Lavender Top (EDTA) tube. Separate plasma within 2 hours of collection in a plastic transport vial and freeze immediately. Ship frozen. Duly filled Test Send Out Consent Form is mandatory.
Report Delivery: Sample by 7th of the month; Report after 2-3 weeks
Method: RIA (Radioimmunoassay)
Test Type: Disorders of Gastrointestinal system
Doctor: Gastroenterologist
Test Department: OS (Operating System)
Pre Test Information: Duly filled Test Send Out Consent Form is mandatory.
Test Details
The VASOACTIVE INTESTINAL POLYPEPTIDE (VIP) test is a diagnostic test used to measure the levels of VIP in the blood. VIP is a hormone produced in the gastrointestinal tract and plays a role in regulating various digestive functions.
The VIP test is primarily used in the diagnosis of VIPoma, a rare type of neuroendocrine tumor that secretes excessive amounts of VIP. VIPomas can cause a condition known as VIPoma syndrome, which is characterized by severe diarrhea, dehydration, electrolyte imbalances, and flushing.
During the VIP test, a blood sample is taken from the patient and analyzed for VIP levels. Elevated levels of VIP in the blood may indicate the presence of a VIPoma. However, other conditions such as pancreatic neuroendocrine tumors and certain types of lung cancer can also cause elevated VIP levels, so additional tests may be necessary to confirm the diagnosis.
The VIP test is typically ordered when a patient presents with symptoms of VIPoma syndrome, such as chronic diarrhea, weight loss, abdominal pain, and flushing. It can also be used to monitor the effectiveness of treatment for VIPoma.
It is important to note that the VIP test is not a routine screening test and is only ordered when there is a clinical suspicion of VIPoma or other conditions associated with elevated VIP levels. The test results should be interpreted in conjunction with the patient’s symptoms and other diagnostic tests.
| Test Name | VASOACTIVE INTESTINAL POLYPEPTIDE VIP Test |
|---|---|
| Components | |
| Price | 2690.0 AED |
| Sample Condition | 3 mL (1.5 mL min.) plasma from1LavenderTop(EDTA)tube.Separate plasmawithin2hoursofcollectionina plastictransportvialandfreeze immediately. Ship frozen.DO NOT THAW. Duly filled Test Send Out Consent Formis mandatory. |
| Report Delivery | Sampleby7thofthemonth;Report after2??3weeks |
| Method | RIA |
| Test type | Disorders of Gastointestinal system |
| Doctor | Gastroenterologist |
| Test Department: | OS |
| Pre Test Information | Duly filled Test Send Out Consent Formis mandatory. |
| Test Details |
The vasoactive intestinal polypeptide (VIP) test is a diagnostic test used to measure the levels of VIP in the blood. VIP is a hormone produced in the gastrointestinal tract and plays a role in regulating various digestive functions. The VIP test is primarily used in the diagnosis of VIPoma, a rare type of neuroendocrine tumor that secretes excessive amounts of VIP. VIPomas can cause a condition known as VIPoma syndrome, which is characterized by severe diarrhea, dehydration, electrolyte imbalances, and flushing. During the VIP test, a blood sample is taken from the patient and analyzed for VIP levels. Elevated levels of VIP in the blood may indicate the presence of a VIPoma. However, other conditions such as pancreatic neuroendocrine tumors and certain types of lung cancer can also cause elevated VIP levels, so additional tests may be necessary to confirm the diagnosis. The VIP test is typically ordered when a patient presents with symptoms of VIPoma syndrome, such as chronic diarrhea, weight loss, abdominal pain, and flushing. It can also be used to monitor the effectiveness of treatment for VIPoma. It is important to note that the VIP test is not a routine screening test and is only ordered when there is a clinical suspicion of VIPoma or other conditions associated with elevated VIP levels. The test results should be interpreted in conjunction with the patient’s symptoms and other diagnostic tests. |
